Fukui Natsu, Golabi Pegah, Otgonsuren Munkhzul, Mishra Alita, Venkatesan Chapy, Younossi Zobair M
Center For Liver Disease and Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia, USA.
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.
Am J Gastroenterol. 2017 Nov;112(11):1700-1708. doi: 10.1038/ajg.2017.290. Epub 2017 Oct 10.
Hospice offers non-curative symptomatic management to improve patients' quality of life, satisfaction, and resource utilization. Hospice enrollment among patients with chronic liver disease (CLD) is not well studied. The aim of tis tudy is to examine the characteristics of Medicare enrollees with CLD, who were discharged to hospice.
Medicare patients discharged to hospice between 2010 and 2014 were identified in Medicare Inpatient and Hospice Files. CLDs and other co-morbidities were identified by International Classification of Diseases-ninth revision codes. Generalized linear model was used to estimate regression coefficients with P-values. Logistic regression was used to calculate odds ratios and 95% confidence intervals.
A total of 2,179 CLD patients and 34,986 controls without CLD met the inclusion criteria. Non-alcoholic fatty liver disease, alcoholic liver disease, and hepatitis C virus (HCV) were the most frequent cause of CLD. CLD patients were younger (70 vs. 83 years), more likely to be male (57.7 vs. 39.3%), had longer hospital stay (length of stay, LOS) (19.4 vs. 13.0 days), higher annual charges ($175,000 vs. $109,000), higher 30-day re-hospitalization rates (51.6 vs. 34.2%), and shorter hospice LOS (13.7 vs. 17.7 days) than controls (all P<0.001). Presence of HCV and congestive heart failure were the strongest contributors to increased total annual costs (34% and 31% higher, P<0.001), increased total annual LOS (26% and 43% higher, P<0.001), and increased 30-day readmission risk (2.20 and 2.19 times, respectively).
Patients with CLD have longer and costly hospitalizations before hospice enrollment as compared with patients without CLD. It was highly likely that these patients were enrolled relatively late, which could potentially lead to less benefit from hospice.
临终关怀提供非治愈性的症状管理,以提高患者的生活质量、满意度和资源利用率。慢性肝病(CLD)患者的临终关怀登记情况尚未得到充分研究。本研究的目的是调查出院后进入临终关怀的医疗保险参保的CLD患者的特征。
在医疗保险住院和临终关怀档案中确定2010年至2014年间出院后进入临终关怀的医疗保险患者。通过国际疾病分类第九版代码确定CLD和其他合并症。使用广义线性模型估计回归系数和P值。使用逻辑回归计算比值比和95%置信区间。
共有2179例CLD患者和34986例无CLD的对照符合纳入标准。非酒精性脂肪性肝病、酒精性肝病和丙型肝炎病毒(HCV)是CLD最常见的病因。CLD患者更年轻(70岁对83岁),男性比例更高(57.7%对39.3%),住院时间更长(住院时长,LOS)(19.4天对13.0天),年度费用更高(175000美元对109000美元),30天再住院率更高(51.6%对34.2%),临终关怀LOS更短(13.7天对17.7天),均与对照组相比(所有P<0.001)。HCV和充血性心力衰竭的存在是年度总成本增加(分别高出34%和31%,P<0.001)、年度总LOS增加(分别高出26%和43%,P<0.001)以及30天再入院风险增加(分别为2.20倍和2.19倍)的最强因素。
与无CLD的患者相比,CLD患者在进入临终关怀之前住院时间更长且费用更高。这些患者很可能登记得相对较晚,这可能导致从临终关怀中获得的益处较少。